Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone353-1649-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.66 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions
What is Nabriva Therapeutics' stock symbol?
Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."
How were Nabriva Therapeutics' earnings last quarter?
Nabriva Therapeutics PLC - (NASDAQ:NBRV) announced its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.04. The biotechnology company had revenue of $0.53 million for the quarter, compared to the consensus estimate of $0.88 million. Nabriva Therapeutics had a negative return on equity of 139.52% and a negative net margin of 3,602.24%. View Nabriva Therapeutics' Earnings History.
When is Nabriva Therapeutics' next earnings date?
What price target have analysts set for NBRV?
7 Wall Street analysts have issued twelve-month target prices for Nabriva Therapeutics' stock. Their forecasts range from $2.00 to $13.00. On average, they anticipate Nabriva Therapeutics' share price to reach $7.71 in the next year. This suggests a possible upside of 303.9% from the stock's current price. View Analyst Price Targets for Nabriva Therapeutics.
What is the consensus analysts' recommendation for Nabriva Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nabriva Therapeutics.
What are Wall Street analysts saying about Nabriva Therapeutics stock?
Here are some recent quotes from research analysts about Nabriva Therapeutics stock:
- 1. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (8/23/2019)
- 2. Northland Securities analysts commented, "We believe Xenleta is positioned to emerge as the 1st empiric monotherapy for treating CABP w/ potential global peak sales of $1B, supported by its significant clinical differentiation from existing therapies. Key Points Xenleta IV and Nabriva announced the FDA approval of Xenleta (lefamulin) IV and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP) in adults. This represents the first approval of a new class antibiotic in nearly 2 decades. Xenleta is a semi-synthetic pleuromutilin that works via a unique mechanism of action by inhibiting the synthesis of bacteria protein necessary of proliferation." (8/16/2019)
- 3. HC Wainwright analysts commented, "We employ a rNPV valuation model, driven by U.S. sales of: (1) lefamulin for CABP through 2028 (peak sales $460M); and (2) CONTEPO for cUTI through 2028 (peak sales $205M). We utilize a 15.0% discount rate for all cash flows, with zero terminal value after 2028, to arrive at our $7 price target (representing risk-adjusted per share values of about $6.50 for lefamulin and about $0.50 for CONTEPO). Risks to the attainment of our PT include failure to obtain FDA approval, unforeseen safety and/or tolerability issues, commercial sales trajectory meaningfully below then consensus expectations, and the dilution to current shareholders from additional equity offering(s)." (8/18/2019)
Has Nabriva Therapeutics been receiving favorable news coverage?
Media stories about NBRV stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nabriva Therapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Nabriva Therapeutics.
Are investors shorting Nabriva Therapeutics?
Nabriva Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,620,000 shares, an increase of 16.4% from the August 30th total of 3,970,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the short-interest ratio is presently 3.1 days. Approximately 8.4% of the shares of the stock are short sold. View Nabriva Therapeutics' Current Options Chain.
Who are some of Nabriva Therapeutics' key competitors?
Some companies that are related to Nabriva Therapeutics include Reata Pharmaceuticals (RETA), Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), United Therapeutics (UTHR), FibroGen (FGEN), Evotec (EVTCY), Allakos (ALLK), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR) and Taro Pharmaceutical Industries (TARO).
What other stocks do shareholders of Nabriva Therapeutics own?
Who are Nabriva Therapeutics' key executives?
Nabriva Therapeutics' management team includes the folowing people:
- Mr. Steven P. Gelone, Pres & COO (Age 51)
- Dr. Colin Broom, Consultant & Director (Age 63)
- Mr. Gary L. Sender, Chief Financial Officer (Age 57)
- Mr. Theodore R. Schroeder, CEO & Director (Age 64)
- Mr. Thomas Lembck, Chief Information Officer
Who are Nabriva Therapeutics' major shareholders?
Nabriva Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.00%), Woodard & Co. Asset Management Group Inc. ADV (0.00%) and Sterling Investment Advisors Ltd. (0.00%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster, Steven P Gelone and Theodore R Schroeder. View Institutional Ownership Trends for Nabriva Therapeutics.
Which major investors are selling Nabriva Therapeutics stock?
NBRV stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have sold Nabriva Therapeutics company stock in the last year include Colin Md Broom, Gary Sender and Steven P Gelone. View Insider Buying and Selling for Nabriva Therapeutics.
Which major investors are buying Nabriva Therapeutics stock?
NBRV stock was acquired by a variety of institutional investors in the last quarter, including Woodard & Co. Asset Management Group Inc. ADV and Sterling Investment Advisors Ltd.. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster and Theodore R Schroeder. View Insider Buying and Selling for Nabriva Therapeutics.
How do I buy shares of Nabriva Therapeutics?
Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Nabriva Therapeutics' stock price today?
One share of NBRV stock can currently be purchased for approximately $1.91.
How big of a company is Nabriva Therapeutics?
Nabriva Therapeutics has a market capitalization of $1.40 billion and generates $9.66 million in revenue each year. The biotechnology company earns $-114,780,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. View Additional Information About Nabriva Therapeutics.
What is Nabriva Therapeutics' official website?
How can I contact Nabriva Therapeutics?
Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN 1 L2, 19406. The biotechnology company can be reached via phone at 353-1649-2000 or via email at [email protected]
MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
